Presentation is loading. Please wait.

Presentation is loading. Please wait.

Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer  Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,

Published byFelix Holtzer Modified over 5 years ago

Similar presentations

Presentation on theme: "Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer  Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,"— Presentation transcript:

1 Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer 
Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci, MedRad, Michael P. MacManus, MD, MRCP, FRCR, FRANZCR, Olga Martin, PhD, MSc, Rodney J. Hicks, MBBS, MD, FRACP, David L. Ball, MD, MBBS, FRANZCR  Journal of Thoracic Oncology  Volume 8, Issue 8, Pages e71-e72 (August 2013) DOI: /JTO.0b013e318292c55a Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Serial PET scans in the patient, focusing on changes in the left upper lobe T3 primary (inset above) and the right lower lobe synchronous T1 primary (inset below). PET, positron emission tomography; SABR, stereotactic ablative radiation therapy. Journal of Thoracic Oncology 2013 8, e71-e72DOI: ( /JTO.0b013e318292c55a) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Serial PET scans in the patient, focusing on changes in the left humerus metastasis (inset above) and the right adrenal metastasis (inset below). PET, positron emission tomography; SABR, stereotactic ablative radiation therapy. Journal of Thoracic Oncology 2013 8, e71-e72DOI: ( /JTO.0b013e318292c55a) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Abscopal Effects after Conventional and Stereotactic Lung Irradiation of Non–Small-Cell Lung Cancer  Shankar Siva, MBBS, FRANZCR, Jason Callahan, BAppSci,"

Similar presentations

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations  Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,

Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm  Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm  Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Similar presentations

Ads by Google